News & events
Urosphere will attend ICS annual meeting and present several scientific communications. (Rotterdam, Netherlands, August 20-24, 2007)
View the posters presented. If you wish to meet UROsphere's senior managers during ICS meeting, please contact us.
The following poster will be presented during the meeting: Palea S, Deba A, Lluel P. Activation of ß3-adrenoceptors inhibits neurogenic contraction in mouseisolated urinary bladder. UROsphere's top management will be present during the congress. If you wish to meet them, please contact us
UROsphere to present scientific results at ICS annual meeting (San Francisco, 29th September – 3rd October 2009)
The following posters will be presented: - Lluel P, Guerard M, Palea S, Julia-Guilloteau V. Duloxetine counteracts bladder overactivity induced by intravesical acetic acid in anesthetized female guinea-pigs through activation of 5-HT receptors. - Lluel P, Chene G, Dubourdeau M, Vergnolle N, Palea S, Coelho AM. Increase in arachidonic acid metabolites in the urine of female rats with cyclophosphamide-induced cystitis. UROsphere's top managers will be present during the...
Following posters will be presented in different sessions: - Deba A, Lluel P, Palea S. Functional evidence of β3-adrenoceptors (β3-AR) in female mouse isolated urinary bladder. - Deba A, Palea S, Parini A, Lluel P. Differential gene expression in bladder hypertrophy following bladder outlet obstruction in mouse. - Lluel P, Guilloteau V, Guerard M, Pietra C, Lovati E, Palea S. Netupitant, a new selective NK1 receptor antagonist, reverses acetic acid-induced bladder overactivity in anesthetized...
UROsphere to present scientific results at EAU annual meeting (Stockholm, Sweden, 17-21 March , 2009)
UROsphere will take part in the European Association of Urology's Annual Meeting and present scientific results on BPH research: Gilles N, Lluel P, Rekik M, Guerard M, Palea S. AdTx1, a new peptidic α1-adrenoceptor antagonist with high affinity and selectivity for human α1A-adrenoceptor subtype: pharmacological characterization. The company's top managers will also present the company's expertise to members of the Medicon Valley biotech cluster (in Sweden and Denmark) in March 2009. To read...
To meet UROsphere top management, please contact usFor more information on this event click here
For more information on this event, click here .
To meet us during this event, please contact usFor more information on this event organized by Info Veille Biotech, click here
UROsphere and Vectalys selected by the SISMIP for their research programme « Discovery of new targets for prostatic pathologies»
The 3SI program for Innovation in the Health Sector is a call for innovative projects reserved to SMEs located in Midi-Pyrenees Region. This program is also supported by the Regional Board of OSEO (France's national agency for industrial innovation), the Regional Board for Research and Technology (DRRT), the Cancer-Bio-Health cluster and Midi Pyrénées Innovation (MPI). UROsphere and Vectalys (a company specialized in viral vector production and cell transduction expertises for gene discovery...
UROsphere announces that OSEO Innovation has awarded a grant over a 2-year period to expand its experimental research platform for early stage drug development. The funding will be used to develop innovative in vivo and in vitro models to offer a wider range of assays for genitourinary pathologies. OSEO innovation (France's national agency for industrial innovation) funds innovative, technology-oriented projects for commercialization in France and abroad.
La page demandée est introuvable. Essayez d'affiner votre recherche ou utilisez le panneau de navigation ci-dessus pour localiser l'article.
SSR240600, a selective neurokinin NK1 receptor antagonist, reduces micturition frequency in anesthetized female guinea-pigs and may be useful as a treatment of human OAB.
Lluel P et al. Aspet-Ray Fuller Symposium, Lower Urinary Tract Disorders, July 6-7, 2002.